S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions|
|Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care|
|Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)|
|Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis|
|Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub|
|Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)|
|Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year|
|Biogen Idec to Report Second Quarter 2014 Financial Results on July 23, 2014|
|New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients|
|Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014|
Click above to view more mutual fund data and stats for biib - Biogen Idec Inc.